SUBSCRIBE
SUBSCRIBE
News   Business

Actelion Ltd. (JOBS) Latest Casualty as Roche (JOBS) Trims Portfolio; Roche Drops Actelion Study in Favor of Own Drug

December 8, 2009 | 
1 min read
Bookmark and Share

Reuters -- Swiss drugmaker Roche Holding is ending a deal with biotech Actelion to develop a drug to treat autoimmune diseases, continuing a portfolio overhaul that began after its Genentech buy.
Alliances
Roche
MORE ON THIS TOPIC
Creative collage illustration of financial business. Two businessmen shaking hands for partners agreement. Conceptual illustration of success deal, corporate ethic, connection.
Cardiovascular disease
Alnylam Unites With Tenaya in Potential $1B+ Pact To Find New Genetic Heart Disease Targets
March 5, 2026
 · 
2 min read
 · 
Heather McKenzie
Modern design with a positive context, a handshake. Concept of help, support and harmony between adults. Modern art collage, trendy magazine style.
Collaboration
Roche Broadens Global Clinical Trial Footprint With $480M+ South Korea Pledge
March 5, 2026
 · 
1 min read
 · 
Tristan Manalac
Podcast
UniQure’s Delay, REGENXBIO’s Rejection Explained, Sarepta’s Ingram Steps Down, More
March 4, 2026
 · 
1 min read
 · 
Heather McKenzie
Businessman receiving large stacks of money from a giant hand. Concept of funding, venture capital, financial support, dividend, and profitable business.
Funding
Teva Bags $400M Backing From Blackstone To Advance Sanofi-Partnered Drug
March 4, 2026
 · 
2 min read
 · 
Tristan Manalac